---
title: "STOK: Net loss widened to $61.6M in Q2 2026 as R&D spending rose and collaboration revenue declined"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294732939.md"
description: "Q2 2026 saw a net loss of $61.6M on $9.3M revenue, with higher R&D and SG&A expenses and lower collaboration revenue. Cash and equivalents were $354.3M, expected to fund operations through early 2028 as late-stage clinical programs advance toward commercialization.Original document: Stoke Therapeutics, Inc. [STOK] SEC 10-Q Quarterly Report — Aug. 3 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-03T20:12:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294732939.md)
  - [en](https://longbridge.com/en/news/294732939.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294732939.md)
generator: "portal-rs"
---

# STOK: Net loss widened to $61.6M in Q2 2026 as R&D spending rose and collaboration revenue declined

Q2 2026 saw a net loss of $61.6M on $9.3M revenue, with higher R&D and SG&A expenses and lower collaboration revenue. Cash and equivalents were $354.3M, expected to fund operations through early 2028 as late-stage clinical programs advance toward commercialization.

Original document: Stoke Therapeutics, Inc. \[STOK\] SEC 10-Q Quarterly Report — Aug. 3 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [STOK.US](https://longbridge.com/en/quote/STOK.US.md)

## Related News & Research

- [Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | STOK Stock News](https://longbridge.com/en/news/296264806.md)
- [Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts](https://longbridge.com/en/news/296156348.md)
- [AIIR: H1'26 saw resilient revenue and stable Adjusted EBITDA amid disruption, with growth set to accelerate](https://longbridge.com/en/news/296476265.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**